Knowledge

Across topics and issues, borders and industries, we have the thought leadership you need to stay ahead of changes in the law.

Follow us:

Publications

Hogan Lovells Publications

Life sciences and health care horizons 2021

Companies in the life sciences and health care industry navigated unparalleled challenges in 2020. The pandemic forced the development and adoption of new technologies and innovations...

Insights

Artificial intelligence in medical devices: the creation of a French regulatory framework
Registered Content

The CNEDiMTS is the French National Authority for Health Committee which evaluates, in particular, medical devices in view of their reimbursement by the French health insurance scheme. The...

Insights

Therapeutic cannabis in France: publication of the decree authorising the experiment
Registered Content

After months of waiting, decree no. 2020-1230 of 7 October 2020 authorises the therapeutic cannabis experiment in France and sets the implementation modalities. Many points are still...

News

Anti-benefits regulations: the last piece of the regulatory puzzle published

Decree no. 2020-730 of 15 June 2020 and the ministerial orders of 7 August 2020 have completed and specified the new anti-benefits regulations which will come into force on 1 October 2020 [f...

News

Getting The Deal Through: Automotive 2020

The drive towards the future of mobility and COVID-19 have made the fourth publication of Getting the Deal Through - Automotive a special edition. It not only explores the particularities...

News

New French anti-benefits regulations - the thresholds finally published

The ministerial orders setting the thresholds for the determination of the notion of negligible value of benefits provided in kind or in cash, as well as the thresholds for the agreements...

News

Strengthening of the French anti-benefits regulations: the wait is over! (almost)

2020 marks a further milestone in stricter controls on HCPs interactions in France. French government has laid the remaining bricks for the new (and stricter) regulatory framework for...

Hogan Lovells Publications

Virtual health horizons 2020

As the world responds to the COVID-19 pandemic, physicians and patients are increasingly turning to virtual health solutions, including telehealth and remote monitoring, as a central facet...

Hogan Lovells Publications

Early Access to Pharmaceutical Products in Major European Markets

The European Medicines Agency (EMA) has committed early patient access to new medicines, particularly those that target an unmet medical need or are of major public health interest.

Loading data